Fresenius completes mAbxience deal. Fresenius stock gains 2.21 percent

Published on 10/16/2026 at 10:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 44.82 on October 16, 2026, 2.21 percent above the Xetra close.

Ownership and earnings shape the picture

Fresenius completed the mAbxience transaction for up to EUR 750.00 million on October 1, 2026.
Second-quarter revenue reached EUR 5.864 billion, while EBIT was EUR 719.00 million.
Fresenius stock trades at EUR 44.82 at 10:02 a.m. CEST at Lang & Schwarz on October 16, 2026, 2.21 percent above the Xetra close of October 15, 2026.
Jefferies maintained a Buy rating and a EUR 55.00 price target on October 2, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) trades at EUR 44.82 at Lang & Schwarz on October 16, 2026 at 10:02 a.m. CEST, up 2.21 percent versus the Xetra close of October 15, 2026 at EUR 43.85. The company completed its acquisition of the remaining 45 percent of mAbxience for up to EUR 750.00 million on September 30, 2026, with the announcement published on October 1, 2026, according to Fresenius.

Full ownership adds a platform

The mAbxience deal gives Fresenius full ownership of its biosimilars platform. The transaction covers a conditional payment of EUR 50.00 million and was financed from existing liquidity and operating cash flow, so no new financing was required, the company said in the same October 1, 2026 release.

Fresenius said mAbxience generated more than EUR 320.00 million in revenue in fiscal year 2025 and operates three production sites with more than 1,300 employees. The platform had four marketed products and eight development candidates at the time of the transaction.

What does Q2 say about margins?

The latest reported quarter provides the operating benchmark. In the second quarter of 2026, group revenue rose 6.00 percent year over year to EUR 5.864 billion, while group EBIT increased 10.00 percent in constant currency to EUR 719.00 million. The EBIT margin expanded by 60 basis points to 12.30 percent, according to Fresenius.

Core earnings per share rose 14.00 percent in constant currency to EUR 0.83 in the second quarter of 2026. Fresenius also raised its full-year 2026 constant-currency core earnings per share growth guidance to 10.00 percent to 15.00 percent from 5.00 percent to 10.00 percent.

Three dated steps to full ownership

On August 5, 2026, Fresenius reported second-quarter revenue of EUR 5.864 billion. On September 7, 2026, it sold 7.8 million Fresenius Medical Care shares for around EUR 300.00 million. On October 1, 2026, it announced the completed mAbxience transaction for up to EUR 750.00 million, according to Fresenius.

Dates investors can mark

Fresenius has scheduled its third-quarter 2026 conference call for November 4, 2026, according to the company financial calendar. Jefferies maintained a Buy rating and a EUR 55.00 price target in a research note dated October 2, 2026, as reported by Markets Insider.

Stock trades above EUR 43.85

The stock's current move places the Lang & Schwarz quote above the latest Xetra close, while the operating figures point to higher revenue, EBIT and core earnings per share in the second quarter.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.